Overview

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Status:
Completed

Trial end date:
2017-08-25

Target enrollment:

Participant gender:

Summary

this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

Phase:

Phase 2

Details

Lead Sponsor:

Taro Pharmaceuticals USA